Prof. Zhiwei Li 李志伟
Chief Physician, Professor
Department of Gastroenterology, Harbin Medical University Cancer Hospital, Harbin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical oncology for gastrointestinal, lung, breast, kidney cancers and melanoma. Specializes in cryoablation, microwave ablation, chemotherapy, immunotherapy, hyperthermic intraperitoneal perfusion, vascular access devices, and CT-guided biopsies.
Dr. Li is a Chief Physician, Professor, and oncology PhD holder with postdoctoral training at MD Anderson Cancer Center. Dr. Li supervises master's students and has led multiple funded research projects. Honors include Heilongjiang Provincial Science and Technology Progress Awards. Dr. Li has authored books and published over 30 academic papers, including SCI-indexed articles.
Professional roles
- Member, Precision Medicine and Tumor MDT Professional Committee, Chinese Research Hospital Association
- Member, MDT Professional Committee, Surgical Branch, Chinese Medical Doctor Association
- Youth Member, Gastrointestinal Subcommittee, China Geriatric Oncology Society
- Standing Committee Member, Tumor Minimally Invasive Therapy Branch, Heilongjiang Medical Association
Name order: in Chinese the family name comes first (Li Zhiwei). Papers usually list the name as Zhiwei Li or Li Z.
Selected publications
29 papers on PubMed matched by name and affiliation; 10 as first or senior author since 2016. Most recent first- or senior-author papers:
- Mol Carcinog, 2026 (senior author): Dynamic Expression Quantitative Trait Locus Mendelian Randomization in Activated CD4-Positive T Cells Nominates SMDT1 and CMTM7 as Candidate Genes in Pancreatic Cancer. PubMed 42900762
- J Adv Res, 2026 (senior author): Noninvasive detection and differentiation of gastric malignancy using cell-free DNA biomarkers. PubMed 41380836
- Mol Carcinog, 2026 (senior author): USP15 Promotes Pancreatic Cancer Progression and Cisplatin Resistance By Activating DNA Damage Repair. PubMed 41950365
- Adv Sci (Weinh), 2025 (senior author): TRIM21 Promotes Tumor Growth and Gemcitabine Resistance in Pancreatic Cancer by Inhibiting EPHX1-Mediated Arachidonic Acid Metabolism. PubMed 39739616
- Oncologist, 2024 (first author): Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreatic ductal adenocarcinoma. PubMed 39226089
- Cell Commun Signal, 2024 (senior author): VDR promotes pancreatic cancer progression in vivo by activating CCL20-mediated M2 polarization of tumor associated macrophage. PubMed 38600588
- J Gastrointest Oncol, 2023 (senior author): Effects of magnetic resonance imaging (MRI)-detected extramural vascular invasion (mrEMVI) and tumor deposits (TDs) on distant metastasis and long-term survival after surgery for stage III rectal cancer: a retrospective study grouped based on the relationship between the bottom of the tumor and peritoneal reflection. PubMed 37201089
- Cancer Med, 2023 (senior author): Prediction scores of postoperative liver metastasis and long-term survival of pancreatic head cancer based on the distance between the mesenteric vessels and tumor, preoperative serum carbohydrate antigen 19-9 level, and lymph node metastasis rate. PubMed 35822597
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion